Auriga

Auriga has published a research report on First Solar (NASDAQ: FSLR) after the company announced yesterday that it has achieved a 14.4% conversion efficiency for its cadmium-telluride based solar PV modules. In the report, Auriga writes, "At $39.92 FLSR trades at ~11.3x our C2012 EPS estimate of $...

According to Auriga, Quiksilver (NYSE: ZQK) price target is raised to $5. Auriga said that ZQK management presented last week at the ICR conference. “We are raising our PT to $5, valuing ZQK shares at 16x our 2013 EPS estimate of $0.32. Reiterate Buy rating.” Quiksilver closed on Friday at $4.26.

According to Auriga, B&G Foods (NYSE: BGS) Hold rating is maintained. Auriga said that David Wenner, B&G Foods CEO, provided an overview of the company's business at the ICR conference that we believe was well received by investors. “We are reiterating our HOLD recommendation and our $23...

According to Auriga, Medifast (NYSE: MED) Buy rating is maintained. Auriga said that Michael McDevitt, Medifast's CEO presented at the ICR conference last week, and had robust attendance in its presentation as well as breakout session. “With the optimistic presentation, we are reiterating our $26...

According to Auriga, Computer Programs & Systems (NASDAQ: CPSI) Buy rating is maintained. Auriga said that the Center for Medicare and Medicaid Services (CMS) released statistics last week ranking Meaningful Use (MU) Attestation numbers by electronic health record (EHR) vendor. “We are...

According to Auriga, Herbalife (NYSE: HLF) price target is raised to $56. Auriga said that Amy Greene, Herbalife's Director of Investor Relations, presented at the ICR conference and had significant participant interest during the presentation as well as during the breakout sessions, which went...

According to Auriga, Spectrum Pharmaceuticals (NASDAQ: SPPI) price target is raised to $18. Auriga said that it believes in the near term, the shares still have momentum to move up due to the favorable impacts of generic leucovorin shortage on Fusilev. “We revised our revenue projection for Q4/...

Auriga has raised the price target on Quiksilver (NYSE: ZQK) from $4 to $5 and maintains its Buy rating.

Auriga reiterates its Buy rating on Celgene (NASDAQ: CELG) as company guidance surpasses street consensus. Auriga says, "We believe the guidance, while not an easy goal to hit, is achievable if management tightly controls expenses. We are eager to learn more about the cost side of the business...

Auriga reiterates its Buy rating on Globe Specialty Metals (NASDAQ: GSM) and lowers its price target to $17 from $21 on key market weakness pressuring price trends. Auriga says, "While GSM remains exposed to macro related headwinds and earnings revision risk, we believe the current valuation and...

Auriga has lowered the price target on Globe Specialty Metals (NASDAQ: GSM) from $21 to $17 and maintains its Buy rating.

Auriga has raised the price target on Celgene (NASDAQ: CELG) from $71 to $82 and maintains its Buy rating.

Auriga initiated coverage on Apple (NASDAQ: AAPL) yesterday with a Buy rating and $550 price target.

Auriga has raised the price target on Seagate Technology (NASDAQ: STX) from $30 to $32 and maintains its Buy rating.

Auriga has published a research report on Boston Beer Company (NYSE: SAM) and has raised the price target from $92 to $100. In the report, Auriga writes, "As 2012 begins, we are raising our price target on Boston Beer to $100 from $92 to reflect our 2013 EPS estimate of $4.54. We continue to use a...